Skip to content

Study · Randomized controlled trial · n = 12 · 1999

7 results

The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin(1-14)(SS) in growth hormone (GH) pulse generation: studies in normal and post cranial irradiated individuals.

Achermann JC, Hindmarsh PC, Robinson IC, Matthews DR, Brook CG

Clinical endocrinology1 Nov 1999Cited by 2 (Europe PMC)

PMID10594518 (opens in a new tab)DOI10.1046/j.1365-2265.1999.00839.x (opens in a new tab)PepBankPUB-10594518
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialActivity measurement

    In adult long-term survivors of childhood brain tumours, continuous GHRH amplified GH release in most subjects compared with spontaneous release.

    In plain wordsIn adult survivors of childhood brain tumours, a steady GHRH infusion raised growth hormone release in most people compared with natural release.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH concentration during continuous GHRH in adult long-term survivors
    Study

    n = 12

    Comparator
    Spontaneous GH release
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    60 ng/kg/minutes · subcutaneous · 24 hAs given in this study (human).

    Measurements

    GH concentration
    4.2 mU/l
    spontaneous
    GH concentration
    6.5 mU/l
    continuous GHRH

    Source sentences

    Summary
    Adult long-term survivors had lower spontaneous GH concentrations and continuous GHRH amplified GH release in most subjects (Spontaneous 4.2 mU/l vs. GHRH 6.5 mU/l, P = 0.008)
    1 context sentence
    Summary · context
    We have used a peptide 'clamp' to assess the relative roles of continuous GHRH and intermittent SS in GH pulse generation in healthy volunteers and short-and long-term survivors of childhood brain tumours.
  2. 02HumanRandomized controlled trialActivity measurement

    In children who had cranial irradiation for brain tumours, continuous GHRH significantly amplified peak GH concentrations in half of them.

    In plain wordsIn children treated with head radiotherapy for brain tumours, a steady GHRH infusion raised peak growth hormone in half of them.

    Peptide
    Sermorelin
    Outcome
    IncreasePeak GH concentration during continuous GHRH in irradiated children
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    60 ng/kg/minutes · subcutaneous · 24 hAs given in this study (human).

    Source sentences

    Summary
    Peak GH concentrations were significantly amplified by GHRH in half of them.
    2 context sentences
    Summary · context
    Spontaneous peak GH release was reduced in the children following irradiation
    Summary · context
    We have used a peptide 'clamp' to assess the relative roles of continuous GHRH and intermittent SS in GH pulse generation in healthy volunteers and short-and long-term survivors of childhood brain tumours.
  3. 03HumanRandomized controlled trialActivity measurement

    In normal adults, continuous GHRH infusion amplified peak GH concentrations compared with spontaneous secretion.

    In plain wordsIn healthy adults, a steady GHRH infusion raised the highest growth hormone levels compared with natural release.

    Peptide
    Sermorelin
    Outcome
    IncreasePeak GH concentration during continuous GHRH in normal adults
    Study

    n: not reported in source

    Comparator
    Spontaneous GH secretion
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    60 ng/kg/minutes · subcutaneous · 24 hAs given in this study (human).

    Measurements

    Median peak GH
    21.1 mU/l
    basal spontaneous
    Median peak GH
    62 mU/l
    continuous GHRH

    Source sentences

    Summary
    Continuous GHRH amplified peak GH concentrations (median basal peak 21.1 mU/l vs. GHRH 62.0 mU/l, P = 0.008)
    1 context sentence
    Summary · context
    We have used a peptide 'clamp' to assess the relative roles of continuous GHRH and intermittent SS in GH pulse generation in healthy volunteers and short-and long-term survivors of childhood brain tumours.
  4. 04HumanRandomized controlled trialActivity measurement

    In normal adults, continuous GHRH infusion did not change the timing of GH pulses.

    In plain wordsIn healthy adults, a steady GHRH infusion did not change when growth hormone pulses happened.

    Peptide
    Sermorelin
    Outcome
    No significant changeGH pulse timing during continuous GHRH in normal adults
    Study

    n: not reported in source

    Comparator
    Spontaneous GH secretion
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    60 ng/kg/minutes · subcutaneous · 24 hAs given in this study (human).

    Source sentences

    Summary
    whilst pulse timing remained unaffected.
    1 context sentence
    Summary · context
    We have used a peptide 'clamp' to assess the relative roles of continuous GHRH and intermittent SS in GH pulse generation in healthy volunteers and short-and long-term survivors of childhood brain tumours.
  5. 05HumanRandomized controlled trialActivity measurement

    In adult long-term survivors of childhood brain tumours, peak GH concentrations during continuous GHRH remained far lower than those of controls.

    In plain wordsIn adult survivors of childhood brain tumours, peak growth hormone with a steady GHRH infusion stayed far lower than in healthy controls.

    Peptide
    Sermorelin
    Outcome
    DecreasePeak GH during continuous GHRH versus controls in adult long-term survivors
    Study

    n: not reported in source

    Comparator
    Matched controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    60 ng/kg/minutes · subcutaneous · 24 hAs given in this study (human).

    Source sentences

    Summary
    but peak concentrations remained far less than those of controls.
    1 context sentence
    Summary · context
    We have used a peptide 'clamp' to assess the relative roles of continuous GHRH and intermittent SS in GH pulse generation in healthy volunteers and short-and long-term survivors of childhood brain tumours.

Studies that did not test the peptide alone2

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 06HumanNot a test of Sermorelin aloneRandomized controlled trialActivity measurement

    In normal adults, continuous GHRH combined with intermittent somatostatin produced regular GH responses when somatostatin was withdrawn.

    In plain wordsIn healthy adults, steady GHRH with on-off somatostatin gave regular growth hormone surges when somatostatin stopped.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH response to somatostatin withdrawal during continuous GHRH in normal adults
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Median GH response
    20.3 mU/l
    GHRH plus intermittent somatostatin

    Source sentences

    Summary
    Combining continuous GHRH with intermittent SS produced regular GH responses upon SS withdrawal (20.3 mU/l; range 2. 3-105.4).
    1 context sentence
    Summary · context
    We have used a peptide 'clamp' to assess the relative roles of continuous GHRH and intermittent SS in GH pulse generation in healthy volunteers and short-and long-term survivors of childhood brain tumours.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 07HumanNot a test of Sermorelin aloneRandomized controlled trialActivity measurement

    In survivors of childhood brain tumours, continuous GHRH with intermittent somatostatin regularized GH release in many patients, but the GH responses remained attenuated.

    In plain wordsIn survivors of childhood brain tumours, GHRH with on-off somatostatin made growth hormone release more regular in many, but responses stayed weak.

    Peptide
    Sermorelin
    Outcome
    MixedGH release with continuous GHRH plus intermittent somatostatin in irradiated patients
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Median GH response
    4.6 mU/l
    GHRH plus intermittent somatostatin

    Source sentences

    Summary
    Combining intermittent SS with continuous GHRH regularized GH release in many patients but the GH responses remained attenuated (4.6 mU/l; 2.5-17.5).
    1 context sentence
    Summary · context
    We have used a peptide 'clamp' to assess the relative roles of continuous GHRH and intermittent SS in GH pulse generation in healthy volunteers and short-and long-term survivors of childhood brain tumours.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.